Cargando…

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study

BACKGROUND: After the reports of severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose of ChAdOx1-S-nCoV-19 vaccine were recommended a second dose of Pfizer’s BNT162b2 vaccine. In hemodialysis patients, we compared the humoral immunogenicity and to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haase, Michael, Lesny, Paul, Anderson, Mark, Cloherty, Gavin, Stec, Michael, Haase-Fielitz, Anja, Haarhaus, Mathias, Santos-Araújo, Carla, Veiga, Pedro Mota, Macario, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792133/ https://www.ncbi.nlm.nih.gov/pubmed/35084719 http://dx.doi.org/10.1007/s40620-022-01247-7

Ejemplares similares

Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study
por: Sim, Wooho, et al.
Publicado: (2023)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
por: Younis, Brima M., et al.
Publicado: (2021)

ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
por: de Jong, Rineke, et al.
Publicado: (2022)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
por: de Graaf, Hans, et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
por: O’Hara, Geraldine A., et al.
Publicado: (2012)

Nonclinical safety assessment of repeated administration and biodistribution of ChAd3‐EBO‐Z Ebola candidate vaccine
por: Planty, Camille, et al.
Publicado: (2020)

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs
por: Finch, Courtney L., et al.
Publicado: (2022)

A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
por: Bauza, Karolis, et al.
Publicado: (2012)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
por: de Barra, Eoghan, et al.
Publicado: (2014)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
por: Hassan, Ahmed O., et al.
Publicado: (2020)

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
por: Ogwang, Caroline, et al.
Publicado: (2013)

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure
por: Biswas, Sumi, et al.
Publicado: (2014)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
por: Elias, Sean C, et al.
Publicado: (2014)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
por: Richardson, Christopher D
Publicado: (2021)

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
por: Osman, Mohamed, et al.
Publicado: (2017)

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
por: Dedroogh, Simon, et al.
Publicado: (2023)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
por: Catry, Emilie, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
por: Bánki, Zoltán, et al.
Publicado: (2022)

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis
por: Lacey, Charles, et al.
Publicado: (2022)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, Alfred B., et al.
Publicado: (2018)

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2018)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
por: Parry, Helen, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tbfigt7cnqa9ie8ittnrs1ge2c